Fournier Industrie Et Sante

Eyevensys

Laboratoires Fournier Sa

Laboratories Fournier S.a.

Luc Lebreton

Francine Behar-Cohen

Patrice Renaut

Christine Dumas

Soth Samreth

Christine Massardier

Cécile Madaras

Romain Benard

Karine Bigot

Patrick Dutartre

Pierre Dodey

Michel Bondoux

Elodie Touchard

Helene-Celine Huguet

Philippe Derrepas

Jean M Rognon

Catherine Derrepas

Philippe Durand

Francine Behar-cohen

Philippe Masson

Olivier Lacombe

Jocelyne Annat

An electroporation device for injecting a product into a ciliary muscle of an eye includes a support having a spherical support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, a first electrode comprising a curved invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, and an injection needle.

Electroporation device

An electroporation device for injecting a product into a ciliary muscle of an eye, said device comprising: a support having a support contact surface extending along a virtual sphere having a radius between 10 and 15 mm, so as to match the outside surface of the eye, a first electrode comprising an invasive electrode needle, a second electrode having an electrically conductive electrode contact surface, optionally an injection needle, wherein the support comprises an insertion guide configured to guide a sliding of said electrode needle and/or injection needle along a respective insertion axis, so that the angle between said insertion axis and a plane tangential to the virtual sphere at the insertion point is less than 40&#xb0;, the insertion point being the point where said insertion axis crosses said virtual sphere.

Benzenesulfonamide derivative compounds corresponding to the general formula (I): and their pharmaceutically acceptable addition salts; a process for preparation of such compounds; pharmaceutical compositions containing such compounds, and the use of such compounds as a pharmacologically active substance, in particular in the treatment of neurodegenerative diseases, cardiovascular diseases, inflammatory diseases; hypercholesterolemia, and diabetes.

LXR receptor modulators

Sulfonylindoline compounds of formula I, wherein R1 through R4, Y and Z have defined meanings, a process for preparation of such compounds, and the use as pharmaceutically active substances, particularly for the treatment or inhibition of neurodegeneration, cardiovascular disease, inflammatory disease, hypercholesterolemia, dyslipidemia, obesity or diabetes.

Indoline compounds

15-deoxyspergualin analogs, their use in therapeutics and their method

The present invention relates to a novel compound selected from the group consisting of: (i) the compounds of the formula ##STR1## in which: A is a group --CO--NH-- or a group --NH--CO--,

15-deoxyspergualin analogs, their method of preparation and their use in

The present invention relates, by way of novel industrial products, to compounds which are structurally related to 15-deoxyspergualin and which have the formula ##STR1## in which: A is a single bond, a group --CH.sub.2 --, a group --CH.sub.2 O--, a group --CH.sub.2 NH--, a group --CH(OH)--, a group --CHF-- or a group --CH(OCH.sub.3)--, and

The present invention relates, by way of novel industrial products, to compounds which are structurally related to 15-deoxyspergualin. These novel compounds have the formula ##STR1## in which: n is equal to 6 or 8 and A is a single bond, CH.sub.2, CHF, CH(OH), CH(OCH.sub.3), CH.sub.2 NH or CH.sub.2 O, and their addition salts.

Growing community of inventors

Dijon, France

Luc Lebreton